

EV 351 923 170 US: Express Mail Number

September 30, 2003: Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop PATENT APPLICATION  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

093003 U.S. PTO  
10/676706  
093003

**NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)**

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

Dean R. Artis,  
David Y. Jackson,  
Thomas E. Rawson,  
Mark E. Reynolds,  
Daniel P. Sutherlin, and  
Mark S. Stanley

Title: **INTEGRIN RECEPTOR INHIBITORS**

**1. Type of Application**

- ☐ This application is for an original, non-provisional application.
- ☐ This is a non-provisional application claiming priority to provisional application no. \_\_, filed \_\_, the entire disclosure of which is hereby incorporated by reference.
- ☒ This is a ☐ continuation-in-part ☒ continuation ☐ divisional application claiming priority under 35 U.S.C. § 120 to application Serial Numbers 10/313,147, filed December 6, 2002, and 09/932,695, filed August 16, 2001, and under 35 U.S.C. § 119(e) to provisional application Serial Number 60/226,626, filed August 18, 2000, the entire disclosures of which are hereby incorporated by reference.

**2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b)  
(Non-provisional)**

47 pages of specification  
7 pages of claims  
1 page(s) of abstract  
0 sheet(s) of drawings  
☐ formal ☐ informal

**3. Declaration or Oath**

*(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)*  
— An executed declaration of the inventor(s) ☐ is enclosed ☐ will follow.

*(for Cont./Div. where inventorship is the same or inventor(s) being deleted)*  
  x   A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).

*(for Cont./Div. where inventor(s) being deleted)*  
— A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

**4. Assignment**

*(for new and CIP applications)*  
— An Assignment of the invention to GENENTECH, INC. ☐ is enclosed with attached Recordation Form Cover Sheet ☐ will follow.

*(for cont./div.)*  
  x   The prior application is assigned of record to Genentech, Inc.

**5. Amendments (for continuation and divisional applications)**

— Cancel in this application original claims \_\_ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

— A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

P1845R1C1

6. **Fee Calculation (37 CFR 1.16)**  
The fee has been calculated as follows:

CLAIMS FOR FEE CALCULATION					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$750.00
Total Claims	16	- 20 =	0	X \$18.00	\$0.00
Independent Claims	1	- 3 =	0	X \$84.00	\$0.00
Multiple dependent claim(s), if any				+ \$280.00	\$0.00
Filing Fee Calculation					\$750.00

7. **Method of Payment of Fees**  
The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$750.00. **A duplicate copy of this transmittal is enclosed.**
8. **Authorization to Charge Additional Fees**  
The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this transmittal is enclosed.**
9. **Additional Papers Enclosed**  
[x] Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449.  
[ ] Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.  
[ ] A new Power of Attorney or authorization of agent.  
[x] Limited Recognition Under 37 C.F.R. 10.9(b)\*
10. **Maintenance of Copendency of Prior Application (for continuation and divisional applications)**  
*[This item must be completed and the necessary papers filed in the prior application if the period set in the prior application has run]*

\_\_\_\_\_ A petition, fee and/or response has been filed to extend the term in the pending prior application until \_\_\_\_\_

\_\_\_\_\_ A copy of the petition for extension of time in the **prior** application is attached.

**11. Correspondence Address:**

X Address all future communications to:

Attn: David W Evans  
Customer No: 09157

Respectfully submitted,

GENENTECH, INC.

Date: September 30, 2003

By: 

David W Evans

Reg. No. \*

Telephone No. (650) 225-1739

1 DNA Way  
South San Francisco, CA 94080-4990

**CUSTOMER NO: 09157**

\* A copy of a document pursuant to 37 C.F.R. §101.9(b) is attached as proof of the authorization of the above to prosecute the attached application. The original of this document is on file in the Office of enrollment and Discipline.